NPPB and miotic rate: In conclusion, the MitraClip® G4 system proved to be a safe and effective option for treating MR, significantly reducing MR severity and improving both functional status and quality of life, with key baseline markers such as NT-proBNP and EuroSCORE II predicting better clinical outcomes.